in vitro News and Research

RSS

TCAD therapy active and synergistic against drug resistant influenza virus strains

Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.

23 Feb 2010

Quidel acquires Diagnostic Hybrids for $130 million

Quidel Corporation, a leading provider of rapid diagnostic tests, has completed its previously announced acquisition of Diagnostic Hybrids, Inc. for approximately $130 million in cash.

20 Feb 2010

Major challenge facing today's toxicologists: Developing test systems to predict toxicity of compounds

Attagene Inc., a leader in developing innovative technologies for analyzing gene regulatory pathways, announced today the online publication of a paper in Chemical Research in Toxicology, a journal of the American Chemical Society, that highlights results of their collaborative work with the Environmental Protection Agency's National Center for Computational Toxicology (NCCT).

19 Feb 2010

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr, an internationally recognized expert in experimental neuropharmacology, to provide specialized microdialysis services to complement PsychoGenics’ in vivo testing capabilities.

19 Feb 2010

UCSF team: NIH ethics guidelines for embryonic stem cell research need to be modified

A UCSF team, led by bioethicist Bernard Lo, MD, recommends that the National Institutes of Health ethics guidelines for embryonic stem cell research be modified to better protect the rights of individuals donating egg or sperm to patients undergoing in vitro fertilization.

19 Feb 2010

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

18 Feb 2010

Asuragen announces agreement to develop and manufacture RNA Control Kits for Affymetrix

Asuragen Inc., a leading molecular biology diagnostic company and service provider, today announced an agreement to develop and manufacture RNA Control Kits for Affymetrix. The RNA Control Kit is intended for use with in vitro transcription (IVT) reagent kits for clinical molecular diagnostic applications that Asuragen has licensed and supplied to Affymetrix.

18 Feb 2010

Research opens up new exploration possibilities for Alzheimer's disease

Researchers at Universitat Aut-noma de Barcelona (UAB) and University of Stockholm have created a computer modelling of the structural malfunctioning of the ApoE4 protein when it enters into contact with the Amyloid beta molecule, the main cause of Alzheimer's disease.

18 Feb 2010

BG Medicine, Merck collaborate in development of novel biomarker for lipid disorder management

BG Medicine, Inc. today announced that it has entered into a research collaboration with Merck, through a subsidiary, for the development and validation of a novel biomarker with potential application in the management of lipid disorders. BG Medicine will pursue development and validation of an immunoassay and investigate its clinical utility as a biomarker. If successful, BG Medicine plans to complete the development and validation studies and seek regulatory clearance for the test.

18 Feb 2010

Researchers adopt new technique to inhibit cancer growth

One of the difficulties of fighting cancer is that drugs often hit other non-cancerous cells, causing patients to get sick. But what if researchers could sneak cancer-fighting particles into just the cancer cells?

17 Feb 2010

Infertility patients from across GTA demand government-funded IVF

Infertility patients from across the GTA gathered at Queen's Park this morning to demand government-funded in vitro fertilization (IVF). Larger than life children's building blocks on the steps of the provincial legislative building spelled out the $550 million the Ontario Expert Panel on Infertility and Adoption says the province could save in long term health care and social services costs by funding IVF.

16 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Researchers identify potential therapeutic targets for treatment of neuroblastoma

A team of researchers, led by Patrick Mehlen, at Universit- de Lyon, France, has identified the protein NT-3 and the cell-surface molecule to which it binds (TrkC) as potential therapeutic targets for the treatment of neuroblastoma - the most frequent solid tumor in young children- by studying human neuroblastoma cells in vitro and after xenotransplantation into mice and chicks.

15 Feb 2010

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.

11 Feb 2010

MUHC commences clinical trial of Exsulin for type 1 diabetes

A clinical trial of Exsulin, an innovative new treatment that targets the underlying cause of type 1 diabetes, has begun at the McGill University Health Centre (MUHC). Under the direction of Dr. George Tsoukas of the MUHC and the McGill University Faculty of Medicine, the study will assess the effectiveness of Exsulin.

11 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.

10 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

New Multi-Cycle program reduces risk of infertility treatment for older mothers

Fertility experts at the Reproductive Science Center of the Bay Area (RSC) announced they have launched a new program from IntegraMed geared toward easing the risk of infertility treatment for qualified women of ages 49 and younger who want to use their own eggs in order to achieve pregnancy.

10 Feb 2010

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

ExThera Medical announced today that the results of a preliminary study (“Cytokines in blood from septic patients interact with surface immobilized heparin”) of its proprietary medical device, Seraph™ extracorporeal affinity therapy, have been published in the current issue of the Journal of the American Society for Artificial Organs (Jan.-Feb. 2010).

9 Feb 2010

in vitro News and Research

TCAD therapy active and synergistic against drug resistant influenza virus strains

Quidel acquires Diagnostic Hybrids for $130 million

Major challenge facing today's toxicologists: Developing test systems to predict toxicity of compounds

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

UCSF team: NIH ethics guidelines for embryonic stem cell research need to be modified

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Asuragen announces agreement to develop and manufacture RNA Control Kits for Affymetrix

Research opens up new exploration possibilities for Alzheimer's disease

BG Medicine, Merck collaborate in development of novel biomarker for lipid disorder management

Researchers adopt new technique to inhibit cancer growth

Infertility patients from across GTA demand government-funded IVF

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Researchers identify potential therapeutic targets for treatment of neuroblastoma

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

MUHC commences clinical trial of Exsulin for type 1 diabetes

Medicinal chemistry paper related to the discovery of CUDC-101 published

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

New Multi-Cycle program reduces risk of infertility treatment for older mothers

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News